Immix Biopharma Announces 100% Overall Response Rate in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

May 22, 2023

(24/7 MARKET NEWS) – Immix Biopharma, Inc. (NASDAQ:IMMX) announced, over the weekend, updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for the treatment of patients with relapsed or refractory multiple myeloma and light chain (AL) amyloidosis. Additional NXC-201 clinical data was presented on eight DARZALEX (daratumumab) relapsed or refractory AL amyloidosis patients.

Immix is trading at $1.89, up $0.25 (+15.24%), on 3.24M premarket shares traded.

Its 52-week range is $0.68 to $3.4499. Not saying that it’s going there, but, if it can get back above $2 there’s not much hard resistance between there and $3.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.